Details of the Drug
General Information of Drug (ID: DM4G6LJ)
Drug Name |
N-phenethyl-2-phenylquinoline-4-carboxamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-phenethyl-2-phenylquinoline-4-carboxamide; 2-Phenyl-quinoline-4-carboxylic acid phenethyl-amide; 65628-69-5; BAS 00329480; ChemDiv3_013317; AC1MIR97; Oprea1_331981; Oprea1_089083; CBDivE_013546; CHEMBL1278237; CTK1I2246; DTXSID50389216; MolPort-001-924-745; HMS1510N07; ZINC3036412; AKOS000577213; MCULE-8602191420; NCGC00320157-01; EU-0063663; AB01317027-02; SR-01000583017; SR-01000583017-1; BRD-K88997350-001-01-1; 4-Quinolinecarboxamide, 2-phenyl-N-(2-phenylethyl)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 352.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 5.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||